Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03136055
Title Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, San Francisco
Indications

neuroendocrine carcinoma

Therapies

Irinotecan + Pembrolizumab

Paclitaxel + Pembrolizumab

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.